Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis

Lia Bally1,2, Philipp Gubler1, Hood Thabit2,3,4, Sara Hartnell5, Yue Ruan2,6, Malgorzata E. Wilinska2,7, Mark L. Evans1,5, Mariam Semmo8, Bruno Vogt6, Anthony P. Coll2,5, Christoph Stettler1 and Roman Hovorka1,2,7

1Department of Diabetes, Endocrinology, Clinical Nutrition & Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; 2Wellcome Trust—MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK; 3Manchester University Hospitals NHS Foundation, Manchester Academic Health Science Centre, Manchester, UK; 4Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; 5Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; 6Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK; 7Department of Paediatrics, University of Cambridge, Cambridge, UK; and 8Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

Inpatient diabetes management of those on hemodialysis poses a major challenge. In a post hoc analysis of a randomized controlled clinical trial, we compared the efficacy of fully automated closed-loop insulin delivery vs. usual care in patients undergoing hemodialysis while in hospital. Compared to control patients receiving conventional subcutaneous insulin therapy, those patients receiving closed-loop insulin delivery significantly increased the proportion of time when a continuous glucose monitor was in the target range of 5.6-10.0 mmol/l by 37.6 percent without increasing the risk of hypoglycemia. Thus, closed-loop insulin delivery offers a novel way to achieve effective and safe glucose control in this vulnerable patient population.

Kidney International (2019) 96, 593–596; https://doi.org/10.1016/j.kint.2019.03.006

KEYWORDS: artificial pancreas; closed-loop insulin delivery; glucose control; hemodialysis

Correspondence: Roman Hovorka, University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome Trust—MRC Institute of Metabolic Science, Box 289, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, UK. E-mail: rh347@cam.ac.uk

Received 9 November 2018; revised 2 March 2019; accepted 7 March 2019; published online 20 March 2019

The prevalence of diabetes is increasing globally, as is the number of people with diabetes requiring hemodialysis.1,2 Glucose management in this population imposes challenges on both patients and health care professionals. End-stage renal disease and hemodialysis predispose these patients to both hypo- and hyperglycemia, which are associated with adverse medical outcomes.4,5 The situation is aggravated when patients are admitted to the hospital due to acute illness.6 Optimal insulin dosing regimens are difficult to establish given the altered glucose metabolism and insulin kinetics in this population.7,8 Hence, glucose management may be better facilitated by an algorithm-driven insulin therapy, also known as closed-loop insulin delivery or artificial pancreas, which is an emerging therapeutic approach combining continuous glucose monitoring with insulin pump therapy to achieve a more physiological means of replacing insulin.9 The role of the control algorithm is to continuously modulate insulin delivery based on real-time sensor glucose values, thereby responding to the inherent variability of insulin requirements. The closed-loop system used in the present study incorporates a control algorithm that is initialized based on the subject’s body weight and estimated total daily insulin dose, and calculates the required insulin infusion rate, aiming at a target glucose level between 5.8 and 7.2 mmol/l by continuously adapting model parameters.10

We hypothesized that fully closed-loop insulin delivery improves glycemic control without increasing the risk of hypoglycemia in inpatients with type 2 diabetes undergoing hemodialysis. Here, we report a post hoc analysis in 17 such inpatients who took part in a randomized parallel-design study.11 The aim of the original study (n = 136) was to assess the efficacy and safety of fully automated closed-loop insulin delivery in comparison with conventional insulin therapy at non-critical care units irrespective of underlying pathophysiology.

RESULTS

Study population

Baseline characteristics were comparable between closed-loop versus control subjects, with mean values as follows: 77%
versus 63% male; age 73 years (SD: 8) versus 67 years (SD: 10); body mass index 31.2 kg/m² (SD: 6.5) versus 32.8 kg/m² (SD: 6.9); glycated hemoglobin 7.1% (SD: 0.6) versus 6.9% (SD: 1.5); diabetes duration 25 years (SD: 13) versus 28 years (SD: 7); total daily insulin dose 42 U/24 h (SD: 25–55) versus 44 U/24 h (SD: 30–69). At recruitment, none of the closed-loop and 4 of the control participants received adjunctive anti-diabetic treatment (all dipeptidyl peptidase-4 inhibitors, with one patient additionally receiving metformin and the other glucagon-like peptide [GLP]-1 receptor agonist therapy). Participants were followed for up to 8.0 days (SD: 3.1) and 7.7 days (SD: 4.8) in the closed-loop and control groups, respectively, and they underwent 4.2 (SD: 1.5) and 3.6 (SD: 2.5) hemodialysis sessions (both differences nonsignificant).

Glycemic control and insulin dose
The proportion of time spent in the target glucose range, which was between 5.6 and 10 mmol/l, was significantly greater in the closed-loop group compared with the control group (69.0% [SD: 12.0] vs. 31.5% [SD: 13.5], respectively; difference 37.6% [SD: 6.2; 95% confidence interval 24.4 to 50.8]; \( P < 0.001 \); primary endpoint; Table 1). The mean sensor glucose level was significantly lower in the closed-loop group than in the control group (8.1 mmol/l [SD: 0.6] vs. 11.0 mmol/l [SD: 2.3]; difference 2.9 mmol/l [SD: 0.8; 95% confidence interval 1.2 to 4.6]; \( P = 0.003 \)). The proportion of time spent at concentrations above the target range (>10 mmol/l) was significantly lower in the closed-loop group (difference 37.2% [SD: 9.2; 95% confidence interval 17.7 to 56.9]; \( P = 0.001 \)), whereas the time spent at concentrations lower than the target range (<5.6 mmol/l) did not differ between groups (\( P = 0.96 \)). Time spent at concentrations lower than 3.0 mmol/l, as well as the burden of hypoglycemia measured by area under the curve less than 3.0 mmol/l, was low and similar between groups (\( P = 0.82 \) and \( P = 0.89 \), respectively). Total daily insulin dose did not differ between groups (\( P = 0.41 \)). Glucose variability, as measured by SD of sensor glucose was significantly reduced compared with conventional insulin therapy (\( P = 0.012 \)). The coefficient of variation of sensor glucose between 24-hour periods was significantly lower in the closed-loop group than in the control group (\( P = 0.008 \)). Twenty-four-hour sensor glucose and insulin delivery profiles are shown in Figure 1. Hypoglycemic (<3.5 mmol/l) or hyperglycemic (>20 mmol/l) events based on capillary glucose were detected, respectively, in 1 control and in none of the closed-loop patients, and in 1 closed-loop and 2 control patients, although none of them had concomitant ketonemia.

DISCUSSION
Increasing evidence shows that closed-loop insulin delivery is superior to conventional insulin treatment in different target groups, such as children, adolescents, pregnant women with type 1 diabetes, and more recently, inpatients with type 2 diabetes.11–13 Glucose management in hospitalized patients undergoing hemodialysis is particularly challenging, and until now, whether a control algorithm can accommodate their specific requirements has been unclear. For the first time, we have shown here that a fully automated closed-loop system clearly improves glucose control in this vulnerable population.

The closed-loop system increased time in the glycemic target range (5.6–10.0 mmol/l) throughout a 24-hour period by 37.6%, compared with control (additional 9 hours). The difference in time spent with target glycemia between closed-loop and control in nonhemodialysis patients of the main study11 was 22.4%, indicating a trend toward a greater beneficial effect of the closed-loop system in the hemodialysis cohort. Hemodialysis patients in the control group spent less than one-third of the time in the target range, possibly due, at least in part, to fear of inducing hypoglycemia. A recent observational study in hospitalized dialysis patients with type 2 diabetes showed14 that 1 in 5 (21.7%) individuals experienced glucose levels <3.0 mmol/l.

Guidelines for inpatient diabetes care suggest14 the use of a basal-bolus insulin regimen. However, implementation can be challenged by high within- and between-day variation in insulin requirements. An outpatient study using euglycemic clamp methodology showed that insulin requirements are reduced by 25% up to 24 hours after hemodialysis.7 Generalizability of this findings to an inpatient setting, however, may not be appropriate, especially in the context of variable daily dialysis schedules and concomitant acute illness.15 Hence, a closed-loop system such as ours, which enables a

Table 1 | Primary and secondary endpoints during the entire study

| Study endpoint | Closed-loop (n = 9) | Control (n = 8) | \( P \) value |
|----------------|--------------------|----------------|-------------|
| Time spent at glucose level in mmol/l (%) | | | |
| 5.6–10.0\(^*\) | 69.0 (12.0) | 31.5 (13.5) | <0.001 |
| >10 | 20.1 (9.8) | 57.4 (25.7) | 0.001 |
| <5.6 | 10.9 (4.5) | 11.1 (14.1) | 0.96 |
| <3.0 | 0.0 (0.0, 0.2) | 0.0 (0.0, 0.6) | 0.82 |
| Mean glucose (mmol/l) | 8.1 (0.6) | 11.0 (2.3) | 0.003 |
| SD of glucose (mmol/l) | 2.3 (0.5) | 3.6 (1.2) | 0.012 |
| CV of glucose (%) | 28.4 (4.9) | 32.3 (8.5) | 0.26 |
| Between days CV of glucose (%) | 13.4 (3.7) | 21.8 (7.3) | 0.008 |
| AUC\(_{<3.0}\) mmol/l (mg/dl × min) | 0.0 (0.0, 2.1) | 0.0 (0.0, 8.8) | 0.89 |
| Total daily insulin dose (U/24 h) | 40.7 (25.7) | 50.3 (20.6) | 0.42 |

\( \text{AUC}_{<3.0} \) area under the curve for a glucose concentration of <3.0 mmol/l per 24-hour period; CV, coefficient of variation.
\(^*\)Primary endpoint.
Data are given as mean (SD), or median (interquartile range).
finely tuned instantaneous glucose-responsive modulation of insulin delivery and continually adapts to changing insulin needs during the day and between days, may offer a more effective and safer diabetes therapy.

One strength of the current study is the random allocation of treatment and the identification of a new target group who may be particularly likely to benefit from a closed-loop system. However, in the absence of randomized outcome trials, the long-term clinical benefits of maintaining effective glycemic control in hemodialysis patients have yet to be established. Findings from observational studies are inconsistent. Although the study with the longest follow-up showed a clear association between high glycated hemoglobin and all-cause mortality, this relationship was found to be either only in patients younger than 60 years or without support. In addition to the unclear accuracy of measures of glycated hemoglobin in dialysis patients, assessments can be challenged by hypoglycemia, which is similarly associated with adverse events. We acknowledge the limitation inherent in a subgroup analysis, such as small sample size and potential confounders that may limit the validity and generalizability of the results. However, our findings provide justification for evaluating further closed-loop insulin delivery use in inpatient and outpatient cohorts on maintenance dialysis.

CONCLUSION
Diabetes management in inpatients with type 2 diabetes undergoing hemodialysis is complex and often results in suboptimal glucose control. Fully automated closed-loop insulin delivery resulted in significantly better glycemic control than did conventional therapy, without increasing the risk of
hypoglycemia, thereby offering a novel treatment modality in this vulnerable population.

METHODS

Study design and participants

In a post hoc analysis of a randomized controlled trial, we compared fully automated closed-loop insulin delivery (n = 9) with conventional insulin therapy (n = 8) in hospitalized patients with type 2 diabetes undergoing hemodialysis for up to 15 days or until hospital discharge. Randomization was stratified according to glycated hemoglobin, body mass index, and total daily insulin dose. The closed-loop group received a subcutaneous study pump (Dana R Diabecare, Sooil, Seoul, Republic of Korea) filled with rapid-acting insulin analogue (Humalog, Eli Lilly, Indianapolis, IN, or Novorapid, Novo Nordisk, Bagsvaerd, Denmark) coupled to a continuous glucose monitor (Freestyle Navigator II, Abbott Diabetes Care, Alameda, CA) by means of a model predictive control algorithm on a computer tablet (Dell Latitude 10 Tablet, Dell, TX). Glucose levels were controlled without announcement or bolusing for meals. The control group received conventional subcutaneous insulin therapy according to local clinical practice, and continuous glucose monitoring was performed in a blinded mode. The study did not interfere with or specify nutritional intake or any other clinical activities. Hemodialysis was carried out according to local practice. Point-of-care capillary glucose measurements were performed as part of usual care by nursing ward staff in both groups.

Statistical analysis

Endpoints were analyzed according to intention-to-treat using unpaired t-tests or nonparametric equivalents for highly skewed variables. GStat software, Version 2.2 (University of Cambridge, Cambridge, UK) and SPSS, Version 21 (IBM Software, Hampshire, UK) were used for calculations. Values are reported as mean (SD) or median (quartile 1 to quartile 3). Two-tailed P values < 0.05 were considered statistically significant.

DISCLOSURE

SH serves as a consultant for Novo Nordisk and for the ONSET group, and reports having received speaker/training honoraria from Medtronic (Minneapolis, MN). MLE reports having received speaker honoraria from Abbott Diabetes Care (Alameda, CA), Novo Nordisk (Bagsvaerd, Denmark), MSD, and Animas, serving on advisory panels for Novo Nordisk (Bagsvaerd, Denmark), Abbott Diabetes Care (Alameda, CA), Medtronic, Roche (Mannheim, Germany), Dexcom, and Cellnovo (Wales, UK). CS reports having received speaker honoraria from Medtronic and Ypsomed (Burgdorf, Switzerland), and serving on advisory panels for Novo Nordisk (Bagsvaerd, Denmark), Medtronic, Roche, and Sanofi (Paris, France). RH reports having received speaker honoraria from Eli Lilly (Indianapolis, IN) and Novo Nordisk (Bagsvaerd, Denmark), serving on advisory panels for Eli Lilly (Indianapolis, IN) and Novo Nordisk (Bagsvaerd, Denmark), and receiving license fees from BBraun and Medtronic. RH and MEW report patents and patent applications related to closed-loop insulin delivery. All the other authors declared no competing interests.

ACKNOWLEDGMENTS

Support for this work was provided by Diabetes UK (#14/0004878), the Swiss National Science Foundation (P1BEP3_165297), and the European Foundation for the Study of Diabetes. Additional support for the Artificial Pancreas work by JDRF was provided by the National Institute for Health Research Cambridge Biomedical Research Centre and the Wellcome Strategic Award (100574/Z/12/Z). Abbott Diabetes Care supplied discounted continuous glucose monitoring devices, sensors, and details of communication protocol to facilitate real-time connectivity. LB received financial support from the University Hospital Bern, University of Bern, and the Swiss Diabetes Foundation. BV is supported by “Fonds pour la recherche thérapeutique,” (funds for therapeutic research) Pully, Switzerland. We are grateful to study volunteers for their participation. We acknowledge support by the ward staff at the Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge; and Inselspital, Bern University Hospital, Bern. Josephine Hayes (University of Cambridge) provided administrative support. Michèle Monnard (University Hospital, Bern) provided data management support in Bern. Jasdeep Mangat provided support for the development and validation of the closed-loop system. Trial registration: NCT01774565.

REFERENCES

1. Kramer A, Pippias M, Noordzij M, et al. The European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary. Clin Kidney J. 2018;11:108–122.
2. Lu Y, Stamn C, Nobre D, et al. Changing trends in end-stage renal disease patients with diabetes. Swiss Med Wkly. 2017;147:w14458.
3. Abe M, Kalantar-Zadeh K. Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nat Rev Nephrol. 2015;11:302–313.
4. Umpierrez GE, Isaacs SD, Bazargan N, et al. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87:978–982.
5. Turchin A, Matheny ME, Shubina M, et al. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care. 2009;32:1153–1157.
6. Gianchandani RY, Neupane S, Heung M. Hypoglycemia in hospitalized hemodialysis patients with diabetes: an observational study. J Diabetes Sci Technol. 2018;12:33–38.
7. Sobngwi E, Enouo S, Ashuntantang G, et al. Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis. Diabetes Care. 2010;33:1409–1412.
8. Sudha MJ, Salam HS, Viveka S, Udupa AL. Assessment of changes in insulin requirement in patients of type 2 diabetes mellitus on maintenance hemodialysis. J Nat Sci Biol Med. 2017;8:64–68.
9. Bally L, Thabit H, Hovorka R. Closed-loop for type 1 diabetes—an introduction and appraisal for the generalist. BMC Med. 2017;15:14.
10. Hovorka R, Canonicco V, Chassin LJ, et al. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas. 2004;25:905–920.
11. Bally L, Thabit H, Hartnell S, et al. Closed-loop insulin delivery for glycemic control in noncritical care. N Engl J Med. 2018;379:547–556.
12. Tauschmann M, Thabit H, Bally L, et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet. 2018;392:1321–1329.
13. Stewart WA, Willinska ME, Hartnell S, et al. Closed-loop insulin delivery during pregnancy in women with type 1 diabetes. N Engl J Med. 2016;375:644–654.
14. American Diabetes Association. 14. Diabetes care in the hospital: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(suppl 1):S144–S151.
15. Iyengar R, Francesz J, Gianchandani R. Inpatient glycemic management in the setting of renal insufficiency/failure/dialysis. Curr Diab Rep. 2018;18:75.
16. Triebswetter S, Gutjahr Lengfeld LJ, Schmidt KR, et al. Long-term survivor characteristics in hemodialysis patients with type 2 diabetes. Am J Nephrol. 2018;47:30–39.
17. Adler A, Casula A, Steenkamp R, et al. Association between glycaemia and mortality in diabetic individuals on renal replacement therapy in the U.K. Diabetes Care. 2014;37:1304–1311.
18. Williams ME, Lacson E, Teng M, et al. Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycaemic control, and survival. Kidney Int. 2006;70:1503–1509.
19. Peacock TP, Shihabi ZK, Bleyer AJ, et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int. 2008;73:1062–1068.
20. Davis SN, Duckworth W, Emanuele N, et al. Effects of severe hypoglycemia on cardiovascular outcomes and death in the Veterans Affairs Diabetes Trial. Diabetes Care. 2019;42:157–163.